Fig 2: (a) Human hepatocytes and human liver cancer HEpG2 cells. Human hepatocytes (HF, Celsis IVT, BioreclamationIVT.com, MD, USA), mouse hepatocytes (MF, Celsis IVT), and human liver cancer HEpG2 cells (HG, ATCC:HB-8065) were used. (b) A two-dimensional culture system was prepared with hepatocytes encapsulated in collagen gel (a mixture of Types I and III (Nitta Gelatin Inc., Osaka)) placed inside the 12-well cell culture inserts (Becton, Dickinson and Co., NJ, USA) and embryoid bodies (EBs) prepared by the suspension culture of ES-D3 cells placed outside. Conversely, an additional system was prepared with EBs encapsulated in collagen gel placed inside the 12-well cell culture inserts and hepatocytes seeded onto a 12-well multi-dish bottom treated with a 0.1% gelatin solution (STEMCELL™ Technologies Inc., Canada) for an hour.

Fig 3: Antimicrobial/cytotoxic activity of compounds 1–3 and 5 against MRSA MB-5393, A. baumannii MB-5973, P. aeruginosa MB-5919, HepG2 (ATCC HB-8065), A. fumigatus ATCC-46645, and C. albicans ATCC-64124.